| Name | Title | Contact Details |
|---|---|---|
William Rompala |
Chief Technology Officer | Profile |
Brad Derstine |
Director, Enterprise Information Technology Systems | Profile |
Wellbiz Brands, Inc. is the nation`s premiere franchisor of wellness, fitness and beauty brands. With more than 600 locations, WellBiz Brands is uniquely qualified to serve the growing needs of the health and beauty conscious consumer through recurring revenue experience-based brands including Elements Massage®, Amazing Lash Studio® and Fitness Together®. Backed by a management team with nearly a century of combined leadership experience, WellBiz Brands accelerates scalable and predictable revenue growth by providing a robust platform of shared services, infrastructure and support. The company claimed three spots on the 2018 Inc. 5000 Fastest Growing Companies list and is headquartered in Englewood, Colorado.
Onvoi is a Roseville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tru Grit set out to craft a line of professional grade fitness products for those who refuse to quit. Our passion for fitness and innovation inspires our team to create fitness equipment that are professional grade at an affordable price. Our products ...
intra-op monitoring services is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Covington, LA. To find more information about intra-op monitoring services, please visit www.iomservices.com
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.